Physician
Tomas, a
Tomas, a was paid $2.19M by Medicaid between Jan 2018 and Jul 2024, across 99 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 12% of everything it billed.
33Billing provider infoTOMAS, A
OTTAWA, IL 61350
OTTAWA, IL 61350
33aNPI1669423695assigned 05/15/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$2.19M
24GClaims333,296
24DCodes billed99
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#34 of 398
Median peer was paid$66K
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,804 | $151K | |
| 2019 | 47,557 | $237K | |
| 2020 | 45,429 | $197K | |
| 2021 | 41,933 | $383K | |
| 2022 | 57,215 | $465K | |
| 2023 | 68,559 | $477K | |
| 2024incomplete | 40,799 | $277K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 12% | 6,174 | 4,730 | $257K |
| 80053 | Comprehensive metabolic panel | 10% | 44,388 | 34,273 | $222K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.3% | 8,870 | 5,715 | $203K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.4% | 53,521 | 38,421 | $163K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.5% | 1,051 | 1,007 | $121K |
| 84443 | Thyroid stimulating hormone (TSH) | 5.5% | 14,288 | 13,021 | $120K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.2% | 1,629 | 1,283 | $113K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.6% | 3,136 | 2,913 | $100K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.9% | 1,538 | 1,478 | $84K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3.1% | 11,279 | 9,842 | $68K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.6% | 2,644 | 2,560 | $57K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 11,234 | 7,424 | $47K |
87 more codes
| 80061 | Lipid panel | 1.7% | 10,788 | $36K |
| 83735 | 1.5% | 8,805 | $32K | |
| 84484 | 1.2% | 6,710 | $27K | |
| 83690 | 1.2% | 7,536 | $27K | |
| 81025 | 1.2% | 12,708 | $26K | |
| 82607 | 1.2% | 4,483 | $26K | |
| 87040 | 1.1% | 2,450 | $23K | |
| 83880 | 1.0% | 2,229 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.0% | 7,397 | $22K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,434 | $20K |
| 87186 | <1% | 3,238 | $20K | |
| 81001 | <1% | 12,641 | $19K | |
| 84439 | <1% | 4,078 | $17K | |
| 85610 | <1% | 6,660 | $17K | |
| 86850 | <1% | 3,490 | $16K | |
| 85730 | <1% | 2,871 | $15K | |
| 82962 | <1% | 9,373 | $13K | |
| 84466 | <1% | 3,103 | $13K | |
| 83605 | <1% | 2,668 | $13K | |
| 86901 | <1% | 4,077 | $13K | |
| 82746 | <1% | 2,337 | $13K | |
| 87081 | <1% | 3,453 | $11K | |
| 82728 | <1% | 2,783 | $11K | |
| 84702 | <1% | 2,136 | $11K | |
| 83540 | <1% | 3,218 | $11K | |
| 86900 | <1% | 4,046 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 407 | $8K |
| 87641 | <1% | 367 | $8K | |
| 88304 | <1% | 395 | $7K | |
| 81003 | <1% | 6,719 | $7K | |
| 88307 | <1% | 137 | $7K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 787 | $7K |
| 85379 | <1% | 1,689 | $6K | |
| 85027 | <1% | 2,205 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 260 | $6K |
| 87428 | <1% | 100 | $6K | |
| 86140 | <1% | 2,739 | $6K | |
| 82570 | <1% | 2,600 | $6K | |
| 80076 | <1% | 1,546 | $6K | |
| 87070 | <1% | 1,086 | $4K | |
| 87147 | <1% | 1,526 | $4K | |
| 82043 | <1% | 1,917 | $4K | |
| 85652 | <1% | 2,718 | $3K | |
| 87400 | <1% | 1,002 | $3K | |
| 84550 | <1% | 1,372 | $3K | |
| 87077 | <1% | 1,082 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 79 | $3K |
| 83970 | <1% | 173 | $3K | |
| 87807 | <1% | 426 | $3K | |
| 80069 | <1% | 507 | $2K | |
| 82274 | <1% | 409 | $2K | |
| 82550 | <1% | 691 | $2K | |
| 83615 | <1% | 575 | $2K | |
| 84100 | <1% | 699 | $2K | |
| 86880 | <1% | 208 | $2K | |
| 84112 | <1% | 30 | $2K | |
| 87088 | <1% | 224 | $1K | |
| 87493 | <1% | 44 | $1K | |
| 82950 | <1% | 397 | $1K | |
| 84703 | <1% | 253 | $962.47 | |
| 85018 | <1% | 683 | $839.02 | |
| 87634 | <1% | 40 | $800.00 | |
| 87185 | <1% | 195 | $706.43 | |
| 87899 | <1% | 103 | $677.10 | |
| 87075 | <1% | 104 | $657.96 | |
| 86920 | <1% | 190 | $648.13 | |
| 80438 | <1% | 24 | $592.32 | |
| 82077 | <1% | 37 | $486.92 | |
| 87427 | <1% | 74 | $453.45 | |
| 83655 | <1% | 70 | $407.99 | |
| 80164 | <1% | 79 | $353.86 | |
| 84156 | <1% | 301 | $350.26 | |
| 80179 | <1% | 18 | $346.58 | |
| 80143 | <1% | 17 | $324.22 | |
| 87045 | <1% | 48 | $292.40 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 34 | $262.90 |
| 87210 | <1% | 106 | $251.45 | |
| 85014 | <1% | 108 | $130.90 | |
| 87046 | <1% | 48 | $127.20 | |
| 82150 | <1% | 30 | $105.01 | |
| 81015 | <1% | 68 | $86.46 | |
| 85384 | <1% | 16 | $84.60 | |
| 83630 | <1% | 12 | $70.92 | |
| 80178 | <1% | 14 | $45.22 | |
| 83721 | <1% | 16 | $37.36 | |
| 86308 | <1% | 12 | $28.80 | |
| 85045 | <1% | 16 | $19.52 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.